LX-P Phase 3 Open Study

A Phase 3, open-label study of LX-P in patients with various pains.

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222338

Enrollment

264

Registered

2013-12-21

Start date

2013-12-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frozen shoulder syndrome, Tendinitis/Tenosynovitis, Peritendinitis, Humeral epicondylitis (Tennis elbow, etc.)

Interventions

investigational material(s) Generic name etc : LX-P INN of investigational material : Loxoprofen Therapeutic category code : 114 Antipyretics, analgesics and anti-inflammatory agents Dosage and Admini

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with well-defined as each target disease and judged as suitable for topical NSAIDs treatment, etc.

Exclusion criteria

Exclusion criteria: Patients with symptoms/findings falling under the contraindications or relative contraindications described in the package insert for loxoprofen sodium hydrate tape, etc.

Design outcomes

Primary

Measure	Time frame
Efficacy (pain assessment by patient)	—

Secondary

Measure	Time frame
Efficacy (overall assessment) Safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026